%0 Journal Article
%A Baldus, O.
%A Waser, R.
%T Experimental and numerical investigations of heat transport and crystallization kinetics in laser-induced modification of barium strontium titanate thin films
%J Applied physics / A
%V 80
%@ 0947-8396
%C Berlin
%I Springer
%M PreJuSER-49726
%P 1553
%D 2005
%Z Record converted from VDB: 12.11.2012
%X Venous thromboembolism is treated with unfractionated heparin or low-molecular-weight heparin, followed by a vitamin K antagonist. We investigated the potential use of idraparinux, a long-acting inhibitor of activated factor X, as a substitute for standard therapy.We conducted two randomized, open-label noninferiority trials involving 2904 patients with deep-vein thrombosis and 2215 patients with pulmonary embolism to compare the efficacy and safety of idraparinux versus standard therapy. Patients received either subcutaneous idraparinux (2.5 mg once weekly) or a heparin followed by an adjusted-dose vitamin K antagonist for either 3 or 6 months. The primary efficacy outcome was the 3-month incidence of symptomatic recurrent venous thromboembolism (nonfatal or fatal).In the study of patients with deep venous thrombosis, the incidence of recurrence at day 92 was 2.9% in the idraparinux group as compared with 3.0% in the standard-therapy group (odds ratio, 0.98; 95% confidence interval [CI], 0.63 to 1.50), a result that satisfied the prespecified noninferiority requirement. At 6 months, the hazard ratio for idraparinux was 1.01. The rates of clinically relevant bleeding at day 92 were 4.5% in the idraparinux group and 7.0% in the standard-therapy group (P=0.004). At 6 months, bleeding rates were similar. In the study of patients with pulmonary embolism, the incidence of recurrence at day 92 was 3.4% in the idraparinux group and 1.6% in the standard-therapy group (odds ratio, 2.14; 95% CI, 1.21 to 3.78), a finding that did not meet the noninferiority requirement.In patients with deep venous thrombosis, once-weekly subcutaneous idraparinux for 3 or 6 months had an efficacy similar to that of heparin plus a vitamin K antagonist. However, in patients with pulmonary embolism, idraparinux was less efficacious than standard therapy. (ClinicalTrials.gov numbers, NCT00067093 [ClinicalTrials.gov] and NCT00062803 [ClinicalTrials.gov].).
%K Anticoagulants: adverse effects
%K Anticoagulants: therapeutic use
%K Female
%K Follow-Up Studies
%K Hemorrhage: chemically induced
%K Heparin: adverse effects
%K Heparin: therapeutic use
%K Humans
%K Incidence
%K Male
%K Middle Aged
%K Oligosaccharides: adverse effects
%K Oligosaccharides: therapeutic use
%K Pulmonary Embolism: drug therapy
%K Pulmonary Embolism: mortality
%K Recurrence
%K Treatment Outcome
%K Venous Thrombosis: drug therapy
%K Venous Thrombosis: mortality
%K Vitamin K: antagonists & inhibitors
%K Anticoagulants (NLM Chemicals)
%K Oligosaccharides (NLM Chemicals)
%K idraparinux (NLM Chemicals)
%K Vitamin K (NLM Chemicals)
%K Heparin (NLM Chemicals)
%K J (WoSType)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:17855670
%U <Go to ISI:>//WOS:000227908400030
%R 10.1007/s00339-004-2904-7
%U https://juser.fz-juelich.de/record/49726